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Due to its putative prebiotic history and innate chemical 
versatility, inositol is a natural carbohydrate central to a plethora 
of cellular signaling processes and recognition events, both inside 
and outside cells, and even between different cell types.1 
Typically through initial phosphorylation events, inositol 
derivatives (e.g., inositol triphosphates, IP3, and lipidated 
phosphatidylinositols, PIs) play key roles in modulating calcium 
signaling, membrane functioning, cell death, cell division and 
cell-to-cell communication.2,3 Additional glycosylation and 
lipidation events eventually yield higher order glycolipids, such 
as the glycosylphosphatidylinositols (GPIs) and poly-
mannosylated lipids, including the phosphatidyl-myo-inositol 
mannosides (PIMs) and lipoarabinomannans (LAMs). These 
glycolipids are essential components in anchoring functional 
proteins on extracellular membrane surfaces and intracellular 
trafficking processes, and are key to host-cell recognition, 
immunological processes, and pathogenic infections.4 
   In this study, we have a view to prepare biosynthetic mimics of 
myo-inositol (azide-surrogates) that have the potential to be 
metabolically incorporated into a chosen cell type (e.g., yeast). 
For this purpose, the modification or introduction of 
bioorthogonal functional groups (“click” functionalities) was 
necessary. Herein, we chose to introduce azide groups to replace 
the different hydroxyl groups of myo-inositol (1) (Figure 1). For 
symmetry reasons, this would result in four regioisomeric series 
of myo-cyclohexanols 2-5, of which two (the 2-series and 5-
series) would be meso (achiral).  
 
 
Figure 1. Azido-deoxy surrogates (2-5) of myo-inositol (1). 
A few routes to the synthesis of optically active azido and 
amino inositols have been reported. Examples of routes start 
from p-benzoquinone5 or conduritol-E6 via chemo-enzymatic 
resolution, and also from chiral sources such as L-quebrachitol.7 
Among various synthetic protocols developed for the synthesis of 
myo-inositol intermediates and its analogues, commercially 
available myo-inositol 1 is the most commonly preferred starting 
material due to its low cost and pre-defined relative 
stereochemistry.8 For myo-inositol, positions C1, C3 and C4, C6 
are equivalent and unsymmetrical protection leads to racemates. 
The chemical synthesis of optically active inositol analogues 
would thus necessitate the resolution of racemic inositol 
intermediates (chemically, enzymatically or via 
desymmetrization techniques)9 or by starting with an alternative 
chiral material (e.g., via the Ferrier carbo-cyclization of sugars).10 
For our biological studies, the racemic azido-inositol series 3 and 
4, and the meso series 2 and 5, were considered sufficient to test 
our hypothesis of metabolic selection and incorporation into live 
cells. Our synthetic routes to make 2-5 are described herein.  
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As a prelude to biomolecular incorporation studies, practical routes to a series of four 
regioisomeric azido-deoxy derivatives of inositol that mimic the natural myo-stereochemistry are 
described. Starting from commercially available myo-inositol, the regioselective and 
stereoselective introduction of azide functionality was achieved at the C-2, C-3, C-4 and C-5 
positions via azide displacement of the corresponding O-sulfonates of suitably protected scyllo-, 
chiro-, epi- and neo-inositols, respectively. Notably, a final one-pot acetolysis method 
conveniently allowed for rapid access to pentaacetate azido-deoxy inositols. Investigations on 
the metabolic incorporation of these myo-inositol azide surrogates in both acetate and free 
alcohol forms are in progress.  










Synthesis of (±)-4-Deoxy-4-Azido myo-Inositols 4: 
We first decided to pursue the dicyclohexylidene diketal 
protection approach reported by Angyal and co-workers11 as a 
starting material over diacetals or diisopropylidene 
derivatives.12,13 This allows for the practical, differential hydroxyl 
protection of myo-inositol (1) as relatively stable trans and cis 
cyclohexylidenes that not only tolerate multi-step synthesis, but 
also result in reactivity differences between the two remaining 
hydroxyl groups. The 1,2,4,5-dicyclohexylidene myo-inositol 6 
was isolated as a white solid in 22% yield after recrystallisation 
from 1:9 acetone/petroleum ether.14 The remaining two isomeric 
ketals (2,3,4,5- and 3,4,5,6-dicyclohexylidenes) can be converted 
to 6 in a sequence of partial deprotection-reprotection steps.11b 
Although yields are low, this method is scalable to multi-grams 
















7: R1 = OH, R2 = H
8: R1 , R2 = C=O
9: R1 = H, R2 = OH




























13: R = Ac, R3 = Bn (15%)
(±)-4a R3 = R = Ac (65%)









Scheme 1. Synthesis of (±)-4-azido myo-inositol analogues 4a,b. Reagents 
and conditions: i. Cyclohexanone, toluene/DMF (1:2), pTSA, 110 °C, 22%; 
ii. BaO, Ba(OH)2·8H2O, BnBr, DMF, 60%; iii. DMP, DCM, rt, 93%; iv. 
NaBH4, EtOH, 0 °C, 76%; v. Tf2O, Py, DCM 0 °C to rt, 73%; vi. 11, AcOH, 
Ac2O, 10% H2SO4 in Ac2O, rt; vii. NaOMe, MeOH, rt, 99%. 
Barium oxide and barium hydroxide chelation-mediated 
benzylation of 6 produced the monobenzylated myo-inositol 
derivative 7 as the major product in 60% yield14 (Scheme 1). The 
free alcohol at the C6 position of the myo-inositol derivative 7 
was subsequently oxidised under Dess-Martin periodinane 
(DMP) conditions to give the desired ketone 8 in excellent yield 
(93%). Stereoselective reduction of 8 by sodium borohydride 
produced the epi-alcohol 915 exclusively. The free C6 alcohol of 
epi-inositol 9 was subsequently activated as its triflate 10 using 
trifluoromethane sulfonic acid anhydride in pyridine.16 In 
accordance with the report of Schlewer et al.,15 azide 
displacement of triflate 10 gave the desired myo-product 11 
together with trace amounts of the enol ether side-product 12 via 
1,2-anti elimination under the basic conditions.  
After several methods were explored, global deprotection of 11 
in the presence of the azide group was eventually achieved in one 
step by acetolysis17 using a mixture of sulphuric acid, acetic 
anhydride and acetic acid to afford the 4-deoxy-4-azido-myo-
inositol pentaacetate 4a5,6 in 65% yield. Minor amounts of the 
partially acetolysed product 3-benzyl-6-azido-myo-inositol 
tetraacetate 13 was also obtained, which could be transformed 
under the same conditions to yield 4a. Further methanolysis in 
the presence of a catalytic amount of sodium methoxide afforded 
the 4-deoxy-4-azido-myo-inositol analogue 4b. Single crystals of 
pentacetate 4a, from 1:1 hexane/ethyl acetate, confirmed the 
stereochemistry unambiguously by X-ray analysis (Figure 2).  
 
Figure 2. X-ray structure of racemic pentaacetate 4-azide analogue 4a.  
Synthesis of meso-5-Deoxy-5-Azido myo-Inositols 5: 
Starting with the dicyclohexylidene diol 6, benzylation of the 
two remaining hydroxyl groups afforded the fully protected 
inositol derivative 14 in excellent yield18 (Scheme 2). The 
kinetically labile and slightly distorted trans ketal of the 
compound 14 was cleaved selectively by controlled acid 
hydrolysis using acetyl chloride in DCM/MeOH (3:1) to afford 
the diol 15 in 68% yield.19 The diol 15 was regioselectively 
benzylated under phase transfer catalyst (tetrabutyl ammonium 
hydrogen sulphate) conditions, resulting in a separable mixture of 
benzylated products 16 and 17.20 Due to difficulties to distinguish 
16 from 17, both alcohols were converted to their corresponding 
methylated derivatives 18a,b for identification purposes. 
Subsequent removal of the cis-ketal unit and global benzylation 
of 18a,b provided the fully protected inositol derivatives 20a and 
20b, respectively. The 1H and 13C NMR of the derived meso-
compound (20b) clearly indicated the structure to be 5-O-methyl-
1,2,3,4,6-penta-O-benzyl myo-inositol. Thus, the corresponding 
starting alcohol 17 was confirmed to possess the C5-free alcohol 















14 15: R1 = R2 = H
16: R1 = Bn, R2 = H (37%)























5a: R = Ac
5b: R = H
13
21: R3 , R4 = C=O
22: R3 = H, R4 = OH

















18a: R1 = Bn, R2 = Me, R3,R4 = C6H10
18b: R1 = Me, R2 = Bn, R3,R4 = C6H10
20a: R1 = Bn, R2 = Me, R3,R4 = Bn
20b: R1 = Me, R2 = Bn, R3,R4 = Bn
19a: R1 = Bn, R2 = Me, R3,R4 = OH




Scheme 2. Synthesis of meso-5-azido myo-inositol analogues 5a,b. Reagents 
and conditions: i. NaH, DMF, BnBr  0 °C, 97%; ii. CH3COCl, DCM, MeOH 
(3:1), 68%; iii. BnBr, Bu4NHSO4, DCM, 5% NaOH, reflux; iv. NaH, DMF, 
MeI, 0 °C to rt, 90%; v. DCM/MeOH (1:1), CH3COCl, rt, 89%; vi. (i); vii. 
DMP, NaHCO3, DCM, rt, 85%; viii. NaBH4, EtOH, rt, 60%; ix. Tf2O, Py, 0 
°C, 71%; x. NaN3, DMF, rt, 83%; xi. Ac2O, AcOH, 10% H2SO4 in Ac2O, 60 
°C, 64%; xii. NaOMe, MeOH, rt, 98%. 
Having identified the C5-OH derivative, the C5-
stereochemistry of 17 was inverted by DMP oxidation followed 
by reduction of the ketone 21 to give the alcohol 22 in the neo-
configuration (Scheme 2). In the reduction step, the original 
alcohol 17 was also formed in 36 % yield, presumably due to 
similar sterics being encountered by the hydride reagent when 
approaching from either the α or β face in 21. The alcohol 22 was 
then converted into its trifluoromethane sulfonate 23 by treatment 
with Tf2O in pyridine. Next, the azide group was installed by a 
clean substitution in an SN2 fashion with sodium azide to 
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regenerate the myo-configured product 24 in good yield. 
Interestingly, no elimination (enol) product was detected, 
presumably due to 1,3-diaxial sterics preventing E2-elimination. 
Compound 24 was then subjected to exhaustive acetolysis to 
form the 5-deoxy-5-azido-myo-inositol pentaacetate 5a.17 In this 
case, an elevated temperature 60 °C was required for complete 
conversion to the pentaacetate 5a.6 The isomeric, partially 
acetolysed, benzyl ether products were also converted to 5a 
under the same acetolysis conditions. Deacetylation of 5a was 
accomplished by methanolysis in the presence of catalytic 
amounts of sodium methoxide to yield 5-deoxy-5-azido-myo-
inositol 5b. Single crystals of compound 5a from 1:1 
hexane/ether confirmed the structure unambiguously by X-ray 
analysis (Figure 3).  
 
Figure 3. X-ray structure of meso pentaacetate 5-azide analogue 5a.  
Synthesis of (±)-3-Deoxy-3-Azido myo-Inositols 3: 
Inspired by the report of Watanabe et al.16b for an efficient SN2 
substitution of C3-inositol triflates, the synthesis of the 3-series 
3a,b was studied by consecutive double substitution at the C3 
position of an inositol intermediate 26, which was obtained from 
the previously synthesized inositol derivative 7 by subsequent 
methoxy methyl (MOM) ether protection to form the fully 
protected 25 and Pd-C  hydrogenolysis (Scheme 3).21 The C3-free 
alcohol 26 was treated with trifluoromethane sulfonic acid 
anhydride in pyridine to yield the corresponding triflate 27, 
which was immediately reacted with potassium acetate in DMA 
to furnish the C3-inverted chiro-acetate 28 in excellent yield 
(96%)16b without elimination, presumably due to the less basic 
nature of the acyl anion as compared to azide species.  
Deacetylation of chiro-28 in the presence of catalytic amounts 
of sodium methoxide gave the axial alcohol 29 (Scheme 3). After 
completion, acidic resin was added to the reaction mixture to 
remove sodium ions by ion exchange. Unexpectedly, the trans 
ketal unit of 29 rearranged into a more stable cis C3/C4-ketal 
(30) by ketal migration under the slightly acidic conditions. 
Hence, a basic aqueous work up procedure using ethylacetate-
water was employed while scaling up. The free axial alcohol in 
29 was subsequently treated with triflic anhydride and pyridine to 
form the triflate 31. Excess pyridine led to formation of an 
eliminated product (35) in minor amounts. Two equivalents of 
pyridine in dichloromethane, however, generated the 
trifluoromethane sulfonylated product 31 in 90% yield without 
elimination. On the other hand, the free axial alcohol of 29 could 
be smoothly mesylated in pyridine as the solvent to form 32 
without elimination, presumably due to the lower leaving group 
aptitude of OMs as compared to OTf.22 The isolated triflate 31 
was examined first. Treatment with sodium azide in DMF 
generated the myo-configured substitution product 33 in low 
yield (15%) together with a minor SN1 substitution product 34 
(10%) and the elimination product 35 in 56% yield.23 In 
comparison, the mesylate derivative 32 failed to undergo azide 
displacement with sodium azide in DMF, even upon heating at 
70 °C. Also, Mitsunobu reaction of the alcohol 29 in order to 







25: R1 = OBn, R2 = H
26: R1 = OH, R2 = H
27: R1 = OTf, R2 = H
28: R1 = H, R2 = OAc
29: R1 = H, R2 = OH
31: R1 = H, R2 = OTf














33: R1 = N3, R2 = H (15%)
34: R1 = H, R2 = N3 (10%)
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ix   (43%)
 
Scheme 3. Synthesis of (±)-3-azido myo-inositol analogues 3a,b. Reagents 
and conditions: i. MOMCl, DIPEA, 0 °C to rt, 87%; ii. EtOAc, THF, 20% 
Pd-C, H2, 60%; iii. Tf2O, Py, DCM, 0 °C, 78%; iv. KOAc, DMA, 70 °C, 
96%; v.  NaOMe, MeOH, rt, 97%; vi. (iii), 90%; vii. MeSO2Cl, py, 94%; viii. 
NaN3, DMF, rt; ix. 31, TMSN3, TBAF, THF, 43%. 
We thus opted to optimise the azide displacement of triflate 31 
by screening differing azide reagents and solvents: NaN3/DMA, 
NaN3/Me2CO/H2O, nBu4NN3/DCM, TMSN3/TBAF/THF. 
Eventually, the combination of excess TMSN3 (8 equiv.) in the 
presence of (0.5 equiv.) of TBAF in THF medium provided myo-
azide 33 in a 43% optimal yield.24 To complete the 3-series, 
global acetolysis of compound 33 formed the desired 3-deoxy-3-
azido myo-inositol pentaacetate 3a5 in moderate yield (Scheme 3) 
under mildly acidic conditions (2% H2SO4 in acetic anhydride). 
Treatment of 33 in dry, ethereal HCl further allowed all acid 
labile protecting groups to be cleaved in one step and 3-deoxy-3-
azido-myo-inositol 3b could be isolated cleanly as a white solid 
after an ether wash.  
Synthesis of meso-2-Deoxy-2-Azido myo-Inositols 2: 
Following the orthoformate protection approach of Kishi et 
al.25, which allows for large differences in reactivity between 
equatorial and axial hydroxyl groups of inositol in terms of 
sterics and electronics,26 a route to the 2-series of azide analogues 
was developed (Scheme 4). The symmetric dibenzyl myo-inositol 
orthoformate 3727 was prepared from the dibenzoate derivative 
36 through a prolonged silver(I) oxide chelation mediated bis-
benzylation28 and aminolysis sequence. The equatorial free 
hydroxyl group of 37 was oxidised under DMP condition to give 
the ketone 38 in excellent yield. Next, stereoselective reduction 
of ketone 38 produced the inverted axial alcohol 39 in the scyllo-
configuration exclusively.25 The rigidity of the orthoformate unit 
presumably accounts for this highly stereoselective reduction 
step. The axially positioned free alcohol of 39 was then 
sulfonylated22 by treatment with methane sulfonyl chloride in 
pyridine to give 40 in excellent yield. At this stage, an SN2 attack 
at C2 of compound 40 was presumed to be sterically challenging. 
Hence, orthoformate cleavage of compound 40 was performed 
first, and the triol 41 was formed by mild methanolysis with 
pTSA.29 Next, the mesylate derivative 41 was heated with 
sodium azide in DMF, which formed the myo-configured azide 
substituted product 42 in moderate yield, along with minor 
amounts of the epoxide 43 and some unreacted starting material 
41. No elimination product was identified in this case; however, 
the reaction required heating at 80 °C, which led to 
decomposition of some material. Final exhaustive acetolysis of 
42 completed the synthesis of the desired 2-deoxy-2-azido-myo-
inositol pentaacetate 2a in good yield. Clean methanolysis under 
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basic conditions regenerated the free hydroxyl groups to 








































2a: R = Ac




37: R1 = OH, R2 = H
38: R1 , R2 = C=O
39: R1 = H, R2 = OH








Scheme 4. Synthesis of 2-azido myo-inositol analogues 2a,b. Reagents and 
conditions: i. (a) Ag2O, BnBr, DMF, rt, (b) (CH3)2CHCH2NH2, MeOH, 
reflux, 70%; ii. DMP, DCM, rt, 95%; iii. MeOH, THF, NaBH4, 87%; iv. 
CH3SO2Cl, py, 92%; v. pTSA, MeOH, 97%; vi. NaN3, DMF, 80 °C; vii. 42, 
Ac2O, AcOH, 15% H2SO4 in Ac2O, 50 °C, 64%; viii. NaOMe, MeOH, 99%.  
Summary 
In this letter, we have described straighforward routes to 
various azido-deoxy inositol analogues through azide installation. 
As a common strategy, we adopted a consecutive SN2 double-
inversion approach on suitably protected inositol derivatives, 
which were derived via convenient oxidation-reduction 
sequences from myo-inositol. A final, global acetolysis step in 
the presence of the azide group (2-15% sulphuric acid in acetic 
anhydride/acid) enabled the direct and convenient synthesis of 
azido-inositol pentaacetate analogues 2a-5a. Methanolysis by 
treatment with catalytic sodium methoxide subsequently 
provided the fully unprotected azido myo-inositol surrogates 2b-
5b cleanly. The routes are convenient and provide sufficient 
material for biological study. Having genuine azide-surrogates of 
myo-inositol in hand, a more concise and diversified strategy is 
under investigation. In the meantime, the metabolic incorporation 
of these modified azido inositol analogues into various inositol 
lipids of yeast cells are in progress, and lipid profiling and 
biosynthetic cell compatabilities will be reported in due course.    
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 5
• Practical routes to all azido-deoxy 
derivatives of myo-inositol are described. 
• Regio- and stereo-controlled introduction of 
azide functionality were achieved. 
• Key scyllo-, chiro-, epi- and neo-inositols 
were prepared as intermediates. 
• A final, one-pot acetolysis gave convenient 
access to the pentaacetate forms. 
• Metabolic, biosynthetic incorporation of 
these azide surrogates are in progress. 
 
